Timothy M. Pawlik

Mar 20, 2025 | ejso.com | Timothy M. Pawlik |Miho Akabane |Jun Kawashima |Abdullah Altaf |Selamawit Woldesenbet |Federico Aucejo | +9 more

Key wordsGallbladder carcinoma (GBC)DiagnosisTumor locationPeritonealSizeImagingGet full text accessLog in, subscribe or purchase for full access. References1. Neculoiu, D. ... The Many Hidden Faces of Gallbladder Carcinoma on CT and MRI Imaging-From A to ZDiagnostics (Basel). 2024; 142. Wernberg, J.A. ∙ Lucarelli, D.D.Gallbladder cancerSurgical Clinics. 2014; 94:343-3603. Hundal, R. ∙ Shaffer, E.A.Gallbladder cancer: epidemiology and outcomeClinical epidemiology. 2014; 99-1094. Mallick, S. ...

Mar 19, 2025 | jamanetwork.com | Diamantis I. Tsilimigras |Timothy M. Pawlik

Molecular Testing and Targeted Therapies in Hepatobiliary Cancers: A Review Podcast (12:47) 0:00 / 0:00 Abstract Importance  Hepatobiliary cancers are heterogeneous and molecularly complex.

Mar 18, 2025 | jamanetwork.com | Diamantis I. Tsilimigras |Timothy M. Pawlik

Importance  Hepatobiliary cancers are heterogeneous and molecularly complex. Recent advances in next-generation sequencing (NGS) have enhanced the understanding of their molecular landscape and enabled deployment of biomarker-based gene- and immune-targeted therapies. This review examines the role of molecular testing and targeted therapies in these malignant neoplasms. Observations  Patients with hepatobiliary cancers have poor outcomes.

Mar 12, 2025 | jamanetwork.com | Rachel A. Greenup |Danny Chu |Timothy M. Pawlik

In the US, individuals with commercial insurance or Medicare-based plans make up approximately 55% and 20% of the population, respectively.1 As a result, administrative and billing data sources are collected by health care organizations, institutions, or government agencies to manage the administrative and financial aspects of health care services. These datasets robustly characterize billable services for individuals receiving inpatient and outpatient medical care and rely on billable codes.

Feb 19, 2025 | ejso.com | Timothy M. Pawlik

Keywords Colorectal cancer Gene signature Overall survival Therapeutic target Machine learning INTRODUCTION Despite advancements in the diagnosis and treatment of patients with colorectal cancer (CRC), mortality remains relatively high.1 In fact, up to 50% of patients develop metastatic CRC (mCRC) at some point in the course of their disease with a subsequent 5-year survival of only 15-40%.2,3 Traditionally, clinicopathological predictors, such as tumor size as well as Tumor/Node/Metastasis...